Outcome of Board Meeting

OrchidPharm~W -- A Dhanuka Group Company ------------------------------------ Date: August 01, 2026 National Stock Exchange of India Limited, SSE Limited Exchange Plaza, Sandra Kurla Complex, Phiroze Jeejeebhoy Towers, Dalal Sandra (E), Mumbai-400051 Street Fort, Mumbai- 400001 Symbol: ORCHPHARMA Scrip Code: 524372 Sub: Intimation under regulation 30- Update on Scheme of Amalgamation Dear Sirj Ma'am, In terms of Regulation 30 of SESI Listing Regulations read with SEBI Master Circular HOj49j14j14(7)2025-CFD-POD2jI/3762j2026 dated January 30, 2026 and in continuation of our earlier intimation dated July 10, 2026 and July 28, 2026, with respect to scheme becoming effective from July 10, 2026 and prior intimation of this Meeting, respectively. We wish to inform you that the Board of Directors of the Company, at its Meeting held today i.e., August 01, 2026, concluded at 13:20 P.M. have, inter alia, approved the issuance and Allotment of 4,45,86,052 fully paid up equity shares of Rs. 10 each, to the eligible shareholders of Dhanuka Laboratories Limited ("Amalgamating Company") as on record date July 23, 2026, pursuant to the scheme of Amalgamation. These shares are proposed to be listed and traded on BSE Limited and National Stock Exchange of India Limited and shall rank pari-passu with the existing equity shares of the Company. Accordingly, the paid up share capital subsequent to the above allotment and cancellation of cross holding of Dhanuka Laboratories Limited has become Rs. 59,88,52,000 (Rupees Fifty nine crore eighty eight lakh fifty two thousand only) divided into 5,98,85,200 (five crore ninety eight lakh eighty five thousand two hundred) shares of Rs. 10 (Rupees Ten) each. Details as required under Regulation 30 read with SEBI Master Circular no. SEBlj HOj49j14j14(7)2025-CFD-POD2jlj3?62j2026, dated January 30, 2026, enclosed herewith as Annexure-I You are requested to take the above intimation on record. Thanking You For Orchid Pharma Limited Kapil Dayya Company Secretary & Compliance Officer Membership No.:Fl0698 +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~W -- A Dhanuka Group Company ----------------------------------- Annexure-I Information as required under Regulation 30 - Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Master Circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30,2026. Particulars Details Type of secu rities proposed to be issued Equity Shares Type of issuance Allotment pursuant to scheme of Amalgamation Total number of securities proposed to be issued or the 4,45,86,052 equity shares ranking total amount for which the securities will be issued pari passu to existing equity shares in case of preferential issue the listed entity shall NA disclose the following additional details to the stock exchange(s) i. names of the investors; ii. post allotment of securities outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors; iii. in case of convertibles intimation on conversion of securities or on lapse of the tenure of the instrument; in case of bonus issue the listed entity shall disclose the NA following additional details to the stock exchange(s): i. whether bonus is out of free reserves created out of profits or share premium account; ii. bonus ratio; iii. details of share capital - pre and post bonus issue; iv. free reserves and/ or share premium required for implementing the bonus issue; free reserves and/ or share premium available for capitalization and the date as on which such balance is available; v. whether the aforesaid figures are audited; vi. estimated date by which such bonus shares would be credited/dispatched f) in case of issuance of depository receipts (ADR/GDR) NA or FCCB the listed entity shall disclose following additional details to the stock exchange(s): i. name of the stock exchange(s) where ADR/GDR/FCCBs are listed (opening - closing status) / proposed to be listed; ii. proposed no. of equity shares underlying the ADR/GDR or on conversion of FCCBs; iii. proposed date of allotment, tenure, date of maturity and coupon offered, if any of FCCB's; iv. issue price of ADR/GDR/FCCBs (in terms of USD and in INR after considerinq conversion rate); +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1, DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151, 159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India. OrchidPharm~~ -- A Dhanuka Group Company ------------------------------------- v. change in terms of FCCBs, if any; details of defaults, if any, by the listed entity in payment of coupon on FCCBs & subsequent up dates in relation to the default, including the details of the corrective measures undertaken (if any); In case of issuance of debt securities or other non- NA convertible securities the listed entity shall disclose following additional details to the stock exchange(s) i. size of the issue; ii. whether proposed to be listed? If yes, name of the stock exchange(s); iii. tenure of the instrument - date of allotment and date of maturity; iv. coupon/interest offered, schedule of payment of coupon/interest and principal; v. charge/security, if any, created over the assets; vi. special right/interest/privileges attached to the instrument and changes thereof; vii. delay in payment of interest / principal amount for a period of more than three months from the due date or default in payment of interest / principal; viii. details of any letter or comments regarding payment/non - payment of interest, principal on due dates, or any other matter concerning the security and lor the assets along with its comments thereon, if any; ix. details of redemption of preference shares indicating the manner of redemption (whether out of profits or out of fresh issue) and debentures; any cancellation or termination of proposal for issuance NA of securities including reasons thereof. +91-44-27444471/72/73 corporate@orchidpharma.com orchidpharma.com CIN: L24222TN1992PLC022994 Registered Office: Corporate Office: Orchid Pharma Limited 15th Floor, Tower 1. DLF Corporate Greens, Sector 74A, Plot Nos. 121-128, 128A-133, 138-151,159-164, SIDCO Industrial Estate, Gurugram - 122004, Haryana, India Alathur, Chengalpattu Dist - 603110, Tamil Nadu, India.